Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for BIIB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 448.90M
March 31, 2026 645.50M
December 31, 2025 511.90M
September 30, 2025 1.272B
June 30, 2025 160.90M
March 31, 2025 259.30M
December 31, 2024 760.90M
September 30, 2024 935.60M
June 30, 2024 625.80M
March 31, 2024 553.20M
December 31, 2023 12.50M
September 30, 2023 592.40M
June 30, 2023 487.00M
March 31, 2023 455.30M
December 31, 2022 -175.00M
September 30, 2022 661.00M
June 30, 2022 736.50M
March 31, 2022 161.80M
December 31, 2021 838.30M
September 30, 2021 805.30M
June 30, 2021 1.227B
March 31, 2021 769.00M
December 31, 2020 -367.10M
September 30, 2020 1.181B
June 30, 2020 1.948B
Date Value
March 31, 2020 1.467B
December 31, 2019 1.960B
September 30, 2019 1.695B
June 30, 2019 1.964B
March 31, 2019 1.460B
December 31, 2018 1.895B
September 30, 2018 1.736B
June 30, 2018 1.099B
March 31, 2018 1.457B
December 31, 2017 1.518B
September 30, 2017 1.628B
June 30, 2017 1.169B
March 31, 2017 235.20M
December 31, 2016 1.577B
September 30, 2016 986.60M
June 30, 2016 995.80M
March 31, 2016 1.016B
December 31, 2015 1.040B
September 30, 2015 895.45M
June 30, 2015 1.047B
March 31, 2015 733.04M
December 31, 2014 932.86M
September 30, 2014 914.03M
June 30, 2014 990.59M
March 31, 2014 104.63M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Ionis Pharmaceuticals, Inc. 565.53M
AbbVie, Inc. 3.436B
Gilead Sciences, Inc. 3.573B
Vertex Pharmaceuticals, Inc. 1.125B
Amgen, Inc. 4.002B